Genmab A/S
Close on Nov 20, 2026
Genmab A/S Cumulative Interventional Clinical Studies Sponsored by Quarter
Cumulative Interventional Clinical Studies Sponsored (Genmab & Merus)
Genmab A/S Cumulative Interventional Clinical Studies Sponsored: 108 in Q3 2026, up 17.4% from a year earlier. That is the highest of the 43 quarters on record here.
Where the Q3 2026 figure comes from
Source: NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
Cumulative interventional trials led by Genmab A/S or Merus N.V. registered on NIH ClinicalTrials.gov by trial start month (monthly through October 2026).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up cumulative Interventional Clinical Studies Sponsored
- Phase 3 Sponsored Interventional Studies21 · Q3 2026
- Phase 2 Sponsored Interventional Studies68 · Q3 2026
- Phase 1 Sponsored Interventional Studies15 · Q3 2026
- Epcoritamab Sponsored Clinical Studies37 · Q3 2026
- Tisotumab Vedotin Sponsored Clinical Studies10 · Q3 2026
- Rinatabart Sesutecan (Rina-S) Sponsored Clinical Studies8 · Q3 2026
- Petosemtamab Sponsored Clinical Studies8 · Q3 2026
Cite this data
StockData. (2026). Genmab A/S Cumulative Interventional Clinical Studies Sponsored, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/ctgov-total-studies
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?